Compare SIGA & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIGA | KIO |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 455.8M |
| IPO Year | 2016 | 2011 |
| Metric | SIGA | KIO |
|---|---|---|
| Price | $3.13 | $10.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 649.1K | 175.3K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | $23.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $10.65 |
| 52 Week High | $9.45 | $12.76 |
| Indicator | SIGA | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 29.02 |
| Support Level | $2.92 | $10.66 |
| Resistance Level | $3.32 | $11.26 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 61.04 | 3.69 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.